

RealRate

PHARMACEUTICAL 2023











RealRate

PHARMACEUTICAL 2023

CorMedix Inc. Rank 109 of 446



The relative strengths and weaknesses of CorMedix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CorMedix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of CorMedix Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 145% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	59,551
Cost of Goods Sold	3.7
Intangible Assets	0
Liabilities, Current	6,311
Liabilities, Non-Current	668
Other Assets	877
Other Compr. Net Income	-4.4
Other Expenses	-586
Other Liabilities	0
Other Net Income	337
Other Revenues	65
Property and Equipment	1,610
Research and Development	10,680
Selling, General and Administrative Expense	20,006

Output Variable	Value in 1000 USD
Assets	62,038
Liabilities	6,979
Expenses	30,104
Revenues	65
Stockholders Equity	55,060
Net Income	-29,702
Comprehensive Net Income	-29,704
Economic Capital Ratio	188%

